Alkem Labs Launches First Cenobamate Drug in India

: Alkem Laboratories has launched NeuCeno (cenobamate), a new anti-seizure medication (ASM) for the treatment of partial-onset seizures in adult patients. This marks the first launch of cenobamate in India, expanding Alkem’s presence in the CNS and specialty-care segment. The introduction of the therapy provides an additional treatment option for adult patients with partial-onset seizures and strengthens Alkem’s domestic product portfolio. The launch also gives the company an opportunity to establish a new specialty brand in an area of neurological care where treatment options continue to evolve. Commercial performance will depend on physician adoption, patient uptake and the company’s ability to build the brand in the Indian market. Overall, the launch represents a positive portfolio-expansion development for Alkem Laboratories. Stock Commentary – Alkem Laboratories ALKEM – POSITIVE (7/10): Launch of NeuCeno (cenobamate) marks the first introduction of this therapy in India and strengthens Alkem’s CNS portfolio. The new specialty product could provide an additional growth opportunity as physician and patient adoption develops.